Supplementary Figure S11 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

Supplementary Figure S11. Heatmap of the 770 transcripts analysed with the Nanostring Pancancer Immune Panel on the baseline biopsies of patients achieving a response at 12 weeks (responders) and non-responders (A). Panel B represents the Gene-set enrichment analysis (GSEA) showing the differential regulation of 22 gene expression signatures on the basis of radiological response at 12 weeks. Methodologic information for the GSEA and its interpretation is provided as Supplementary Methods.